Advances in cellular immunotherapy for malignant melanoma;Avances en inmunoterapia celular contra el melanoma maligno

Revista Medica de Chile

Volumn 132, Issue 9, 2004, Pages 1115-1126

  Lopez, Mercedes ^a   Escobar, Alejandro ^a   Alfaro, Jorge ^b   Fodor, Miguel ^b   Larrondo, Milton ^b   Ferrada, Carlos ^b,c   Salazar Onfray, Flavio ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^c UNIVERSIDAD DEL DESARROLLO   (Chile)

Author keywords

Dendritic cells; Immunotherapy; Interleukin 2; Malignant melanoma

Indexed keywords

INTERLEUKIN 2;

BLOOD; CELL LYSATE; DENDRITIC CELL; EXPERIENCE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOTHERAPY; LOW DRUG DOSE; MELANOMA; REVIEW; SURVIVAL; T LYMPHOCYTE; VACCINATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY; INTERLEUKIN-2; MELANOMA; PULSE THERAPY, DRUG; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 12444321993     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. PAWLIK TM, SONDAK VK. Malignant melanoma: current state of primary and adjuvant treatment. Crit Rev Oncol Hematol 2003; 45: 245-64.
2. MEDINA E, KAEMPFFER A. Mortalidad del adulto en Chile. Rev Med Chile 2000; 128: 1144-9.
3. SILVERMAN LB, WEINSTEIN HJ. Treatment of childhood leukemia. [Review]. Curr Opin Oncol 1997; 9: 26-33.
4. VEY N, VIENS P, FOSSAT C, OLIVE D, SAINTY D, BAUME D ET AL. Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation. Eur Cytokine Netw 1997; 8: 389-94.
5. RICHARDS JM, GALE D, MEHTA N, LESTINGI T. Combination of chemotherapy with interleukin-2 and interferon alpha for the treatment of metastatic melanoma. J Clin Oncol 1999; 17: 651-7.
6. ROSENBERG SA, SPIESS P, LAFRENIERE R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986; 233: 1318-21.
7. PREHN RT, MAIN JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957; 18: 769-78.
8. LEIN G, SJOGREN HO, KLEIN E, HELLSTROM KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960; 20: 1561-72.
9. TOPALIAN SL, SOLOMON D, ROSENBERG SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142: 3714-25.
10. ITOH K, PLATSOUCAS DC, BALCH CM. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 1988; 168: 1419-41.
11. BARTH RJ JR, MULE JJ, SPIESS PJ, ROSENBERG SA. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991; 173: 647-58.
12. BOON T, CEROTTINI JC, VAN DEN EYNDE B, VAN DER BRUGGEN P, VAN PEL A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12: 337-65.
13. BOON T, GAJEWSKI TF, COULIE PG. From defined human tumor antigens to effective immunization Immunol. Today 1995; 16: 334-6.
14. ZINKERNAGEL RM, DOHERTY PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974; 248: 701-2.
15. TOWNSEND AR, GOTCH FM, DAVEY J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 1985; 42: 457-67.
16. FALK K, ROTZSCHKE O, DERES K, METZGER J, JUNG G, RAMMENSEE HG. Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J. Exp Med 1991; 174: 425-34.
17. SLINGLUFF CL JR, COX AL, HENDERSON RA, HUNT DF, ENGELHAND VH. Recognition of human melanoma cells by HLA-A2.1-restricted CTL is mediated by at least six shared peptide epitopes. J Immunol 1993; 150: 2955-63.
18. TRAVERSARI C, VAN DER BRUGGEN P, LUESCHER IF, LURQUIN C, CHOMEZ P, VAN PEL A ET AL. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176: 1453-7.
19. GAUGLER B, VAN DEN EYNDE P, VAN DER BRUGGEN P, ROMERO J, GAFORIO E, DE PLAEN B ET AL. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179: 921-30.
20. TANZARELLA S, RUSSO V, LIONELLO I, DALERBA P, RIGATTI D, BORDIGNON C ET AL. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. Cancer Res 1999; 59: 2668-74.
21. WÖLFEL T, HAUER M, SCHNEIDER J, SERRANO M, WÖLFEL C, KLEHMANN-HIEB E ET AL. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269; 1281-4.
22. COULIE PG, BRICHARD V, VAN PEAL T, WÖLFEL J, SCHNEIDER C, TRAVERSAKI S ET AL. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994; 180: 35-42.
23. KAWAKAMI Y, ELIYAHU CH, DELGADO PF, ROBBINS K, SAKAGUCHI E, APPELLA J ET AL. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91: 6458-62.
24. KAWAKAMI Y, ELIYAHU CH, DELGADO PF, ROBBINS L, RIVOLTINI SL, TOPALIAN T ET AL. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91: 3515-9.
25. KAWAKAMI YS, ELIYAHU K, SAKAGUCHI PF, ROBBINS L, RIVOLTINI J, YANNELLI E. Identification of the immunodominant peptides of the Mart-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180: 347-52.
26. KAWAKAMI YS, ELIYAHU C, JENNINGS K, SAKAGUCHI X, KANG S, SOUTHWOOD P ET AL. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995; 154: 3961-8.
27. BRICHARD V, VAN PEL A, WÖLFEL T, WOLFEL C, DE PLAEN E, LETHE B ET AL. The tyrosinase gene coded for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 + melanoma. J Exp Med 1993; 178: 489-95.
28. CHHAJLANI V, WIKBERG JES. Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA. FEBS Letters, 1992; 309: 417-20.
29. SALAZAR-ONFRAY F, NAKAZAWA T, CHHAJLANI V, PETERSSON M, KARRE K, MASUCCI G ET AL. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Cancer Res 1997; 57: 4348-55.
30. SALAZAR-ONFRAY F, LÓPEZ M, LUNDQVIST A, AGUIRRE A, ESCOBAR A, SERRANO A ET AL. Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. Br J Cancer 2002; 87: 414-22.
31. DELVES PJ, ROITT IM. The immune system. First of two parts. N Engl J Med. 2000; 343: 37-49.
32. BANCHEREAU J, STEINMAN RM. Dendritic cells and the control of immunity. (Review) Nature 1998; 392: 245-52.
33. LIU Y, JANEWAY CA JR.. Cells that present both specific ligand and co-stimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cell. Proc Natl Acad Sci 1992; 89: 3845-9.
34. STEINMAN RM, COHN ZA. Identification of a novel cell type in peripheral lymphoid organs of mice functional properties in vitro. J Exp Med 1973; 137: 1142-62.
35. SALLUSTO F, LANZAVECCHIA A. Efficient presentation of soluble antigen by cultured human dendritic cells is mainteined by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 1994; 179: 1109-18.
36. REDDY A, SAPP M, FELDMAN M, SUBKLEWE M, BHARDWAJ N. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 1997; 90: 3640-6.
37. YOUNG JW, SZABOLCS P, MOORE MAS. Identification of dendritic cell colony-forming units among normal CD4+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor α. J Exp Med 1995; 182: 1111-20.
38. SALLUSTO F, CELLA M, DANIELI C, LANZAVECCIHIA A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products. J Exp Med 1995; 182: 389-400.
39. REIS E SOUSA C, STAHL PD, AUSTYN JM. Phagocytosis of antigens by langerhands cells in vitro. J Exp Med 1993; 178: 509-19.
40. BANCHEREAU J, BRIENE F, CAUX C, DAVOUST J, LEBECQUE S, LIU YJ. Immunology of dendritic cells. Ann Rev Immunol 2000; 18: 767-811.
41. FANGER NA, WARDWELL KL, SHEN L, TEDDER TF, GUYRE PM. Type I (CD64) and type II (CD32) Fcggg receptor-mediated phagocytosis by human blood dendritic cells. J Immunol 1996; 157: 541-8.
42. ALBERT ML, PEARCE SF, FRANCISCO LM, SAUTER B, ROY P, SILVERSTEIN RL. A immature dendritic cells phagocytose apoptotic cells via αcvβ5 and CD36, cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188: 1359-68.
43. RUSSO V, ZHOU D, SARTIRANA C, ROVERE P, VILLA A, ROSSINI S ET AL. Acquisition of intact allogeneic human leukocyte antigen molecules by human dendritic cells. Blood. 2000; 95: 3473-7.
44. LAMBRECHT BN, SALOMON B, KLATZMANN D, PAUWELS RA. Dendritic cells chronic eosinophilic airway inflammation are required for the development of in response to inhaled antigen in sensitized mice. J Immunol 1998; 160: 4090-7.
45. RESCIGNO M, GRANUCCI F, CITTERIO S, FOTI M, RICCIARDI-CASTAGNOL P. Coordinated events during bacteria-induced DC maduration. Immunol Today 1999; 20: 200-3.
46. PAGLIA P, CHIODONI C, RODOLFO M, COLOMBO MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183: 317-22.
47. PORGADOR A, GILBOA E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995; 182: 255-60.
48. SONG W, KONG H, CARPENTER H, TORH H, GRANSTEIN R, RAFH S. Crystal Dendritic Cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity J Exp Med 1997; 186: 1247-56.
49. BOCZKOWSKI D, NAIR SK, SNYDER D, GILBOA E Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 465-72.
50. TOES R, VAN DER VOORT EIH, SCHOENBERGER SP, DRIJFHOUT JW, VAN BLOOIS L, STORM G. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells J Immunol 1998; 160: 4449-56.
51. SHULER G, SHULER-THURNER B, STEINMAN RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15: 138-47.
52. NESTLE FO, ALIJAGIC S, GILLIET M, SUN Y, GRABBE S, DUMMER R Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dentritic cells. Nature Med 1998; 4: 328.
53. THURNER B, DIECKMANN D, KEIKAVOUSSI P, BENDER A, MACZEK C, JONULEIT H. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol 2000; 165: 3492-6.
54. THURNER B, SCHULTZ ES, BERGER TG, WEINLICH G, EBNER S, WOERL P. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002; 195: 1279-88.
55. SMITH KA. T-cell growth factor. Immunol Rev 1980; 51: 257-78.
56. ATKINS MB. Interleukin-2: clinical applications. Semin Oncol 2002; 29(3 Suppl 7): 12-7.
57. SMITH KA. Interleukin-2: inception, impact, and implications. Science 1988; 240: 1169-76.
58. WALDMANN TA, GOLDMAN CK, ROBB RJ, DEPPER JM, LEONARD WJ, SHARROW SO. Expression of interleukin 2 receptors on activated human B cells. J Exp Med 1984; 160: 1450-66.
59. ZUBLER RH, LOWENTHAL JW, ERARD F, HASHIMOTO N, DEVOS R, MACDONALD HR. Activated B cells express receptors for, and proliferate in response to, pure interleukin 2. J Exp Med 1984; 160: 1170-83.
60. HENNEY CS, KURIBAYASHI K, KERN DE, GILLIS S. Interleukin-2 augments natural killer cell activity. Nature 1981; 291: 335-8.
61. SIEGEL JP, SHARON M, SMITH PL, LEONARD WJ. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science 1987; 238: 75-8.
62. GRIMM EA, MAZUMDER A, ZHANG HZ, ROSENBERG SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823-41.
63. DJEU JY, LIU JH, WEI S, RUI H, PEARSON CA, LEONARD WJ. Function associated with IL-2 receptor-beta on human neutrophils. Mechanism of activation of antifungal activity against Candida albicans by IL-2. J Immunol 1993; 150: 960-70.
64. KJELDSEN-KRAGH J, QUAYLE AJ, SKALHEGG BS, SIOUD M, FORRE O. Selective activation of resting human gamma delta T lymphocytes by interleukin-2. Eur J Immunol 1993; 23: 2092-9.
65. ESPINOZA-DELGADO I, BOSCO MC, MUSSO T, GUSELLA GL, LONGO DL, VARESIO L ET AL. Interleukin-2 and human monocyte activation . J Leukoc Biol 1995; 57: 13-9.
66. TANIGUCHI T, MATSUI H, FUJITA T, TAKAOKA C, KASHIMA N, YOSHIMOTO R, ET AL Structure and expression of a cloned cDNA for human interleukin-2. Nature 1983; 302: 305-10.
67. ROSENBERG SA, GRIMM EA, MCGROGAN M, DOYLE M, KAWASAKI E, KOTHS K ET AL Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984; 22: 1412-4.
68. ROSENBERG SA, LOTZE MT, MUUL LM, CHANG AE, AVIS FP, LEITMAN S ET AL. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Eng J Med 1987; 316: 889.
69. ROSENBERG SA. The development of new immunotherapies for the treatment of cancer using interleukin-2. Ann Surg 1988; 208: 121-35.
70. FISHER RI, COLTMAN CA JR, DOROSHOW JH, RAYNER AA, HAWKINS MJ, MIER JW ET AL. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells: a phase II clinical trial. Annals of Internal Medicine 1988; 108: 518-23.
71. WEISS GR, MARGOLIN KA, ARONSON FR, SZNOL M, ATKINS MB, DUTCHER JP ET AL. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. Journal of Clinical Oncology 1992; 10: 275-81.
72. ROSENBERG SA, YANG JC, TOPALIAN SL, SCHWARTZENTRUBER DJ, WEBER JS, PARKINSON DR ET AL. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271: 907-13.
73. SMITH KA. Lowest dose interleukin-2 immunotherapy. Blood 1993; 81: 1414-23.
74. MASUCCI G, SVENSSON A, HANSSON M, HANSSON J, NAKAZAWA T, SALAZAR F ET AL. Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis). J Hematother 1997; 6: 253-60.
75. FENTON RG, STEIS RG, MADARA K, ZEA AH, OCHOA AC, JANIK JE ET AL. A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma. J Immunother Emphasis Tumor Immunol 1996; 19: 364-74.
76. ROSENBERG SA, ZHAI Y, YANG JC, SCHWARTZENTRUBER DJ, HWU P, MARINCOLA FM ET AL. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998; 90: 1894-900.
77. OOSTERWIJK-WAKKA JC, TIEMESSEN DM, BLEUMER I, DE VRIES IJ, JONGMANS W, ADEMA GJ ET AL. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 2002; 25: 500-8.
78. MACKALL CL, FLEISHER TA, BROWN MR, MAGRATH IT, SHAD AT, HOROWITZ ME ET AL. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84: 2221-8.
79. SALAZAR-ONFRAY F. Interleukin-10: a strategy used by tumors to escape from immunesurveillance. (Review). Med Oncol 1999; 16: 86-94.
80. DUDLEY ME, WUNDERLICH JR, ROBBINS PF, YANG JC, HWU P, SCHWARTZENTRUBER DJ ET AL. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-4.